CureVac N.V [CVAC] stock is trading at $5.52, down -0.90%. An important factor to consider is whether the stock is rising or falling in short-term value. The CVAC shares have gain 23.21% over the last week, with a monthly amount glided 61.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CureVac N.V [NASDAQ: CVAC] stock has seen the most recent analyst activity on June 13, 2025, when Jefferies downgraded its rating to a Hold but kept the price target unchanged to $5 for it. Previously, Leerink Partners downgraded its rating to Market Perform on April 25, 2024, and dropped its price target to $4. On June 08, 2023, SVB Securities initiated with a Outperform rating and assigned a price target of $13 on the stock. UBS upgraded its rating to a Buy and increased its price target to $18 on January 19, 2023. Jefferies upgraded its rating to a Buy and raised its price target to $21 on January 09, 2023. BofA Securities downgraded its rating to Underperform for this stock on January 21, 2022, and downed its price target to $20. In a note dated January 18, 2022, JMP Securities initiated an Mkt Outperform rating and provided a target price of $52 on this stock.
CureVac N.V [CVAC] stock has fluctuated between $2.37 and $5.72 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. CureVac N.V [NASDAQ: CVAC] shares were valued at $5.52 at the most recent close of the market. An investor can expect a potential drop of -9.42% based on the average CVAC price forecast.
Analyzing the CVAC fundamentals
CureVac N.V [NASDAQ:CVAC] reported sales of 574.49M for the trailing twelve months, which represents a drop of -93.00%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.36%, and Net Profit Margin reading is 0.3%. To continue investigating profitability, this company’s Return on Assets is posted at 0.2, Equity is 0.29 and Total Capital is 0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.47 points at the first support level, and at 5.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.56, and for the 2nd resistance point, it is at 5.61.
Ratios To Look Out For
For context, CureVac N.V’s Current Ratio is 7.65. On the other hand, the Quick Ratio is 7.65, and the Cash Ratio is 6.66. Considering the valuation of this stock, the price to sales ratio is 2.16, the price to book ratio is 1.78 and price to earnings (TTM) ratio is 6.12.
Transactions by insiders
Recent insider trading involved Thaminda Ramanayake, affiliate, that happened on May 07 ’25 when 6986.0 shares were purchased. affiliate, Myriam Mendila completed a deal on Jan 07 ’25 to buy 17839.0 shares. Meanwhile, affiliate Pierre Kemula bought 51523.0 shares on Jan 07 ’25.
